**Research Highlights**

(1)Heteroduplex analysis was used to conduct gene screening of eight exons of *Nurr1* gene among Parkinson\'s disease patients and controls.(2)Missense mutations in exons 2 and 3 of the *Nurr1* gene were found in Chinese patients with Parkinson\'s disease.

**Abbreviations**

DA, dopaminergic neurons; TH, tyrosine hydroxylase

INTRODUCTION {#sec1-1}
============

Parkinson\'s disease manifests as many involuntary movement disorders, including tremor, reduced action and raised muscle tension. It is estimated that the number of Parkinson\'s disease patients aged \> 65 years in China is \> 2 000 000, and the morbidity is increasing\[[@ref1]\]. The molecular mechanisms underlying this disease are still not fully understood. A series of Parkinson\'s disease-related genes have been identified, such as α-synuclein, Parkin 1--18 and others. However, the rare mutation rates of these genes still cannot account for most Parkinson\'s disease molecular pathogenesis. Therefore, identification of gene polymorphisms controlling the production of dopaminergic neurons (DA), as well as their development and maintenance of function after maturity will provide new insights into the pathogenesis of Parkinson\'s disease.

The *Nurr1* gene consists of eight exons and seven introns. The gene\'s upstream 5' flanking region contains a transcription promoter region and an adjusting zone. The first ATG codon from the 5' end in exon 3 is the translation start point. A stop codon is located in the upstream region of exon 8, while the 3' untranslated region of exon 8 contains multiple repetitive ATTTA sequences, and plays a stabilizing role in mRNA transcription. *Nurr1* is an immediate early gene and acts as gene transcription factor\[[@ref2][@ref3][@ref4]\]. The *Nurr1* gene plays a dominant role in DA neuronal development, differentiation and the maintenance of function after maturation\[[@ref5]\]. Zetterström *et al*\[[@ref6]\] reported that Nurr1 knockout rats died 1 day after birth, and that DA neurons were completely lacking in the ventral area of the brain. By contrast, tyrosine hydroxylase (TH) was detected in other regions, demonstrating that the *Nurr1* gene plays a key role in maintaining the functions of mature DA neurons in the midbrain. Grimes *et al*\[[@ref7]\] detected a *Nurr1* gene polymorphism in the patients with Parkinson\'s disease, and showed that the *Nurr1* expression level was decreased by 45% in blood lymphocytes. Studies revealed that Parkinson\'s disease patients carry exon 1 and intron 6 polymorphisms in the *Nurr1* gene\[[@ref8][@ref9]\].

It was reported that the *Nurr1* gene participates in the control of central dopamine metabolism\[[@ref10]\], and that the *Nurr1* expression level was significantly decreased with age in mesencephalic substantia nigra cells of the exon 3^+/-^ heterozygous mouse, accompanied by decreased dopamine levels\[[@ref11]\]. Nurr1 regulated TH metabolism and induced DA neuron formation. Transfection of embryonic stem cells with the *Nurr1* gene can significantly improve their differentiation into DA neurons\[[@ref12][@ref13][@ref14]\]. Thus, it can be speculated that *Nurr1* is a key gene for DA neuron development, differentiation and maintenance of functions, and that a lack of *Nurr1* will increase the environmental toxin sensitivity of neurons. Therefore, we used heteroduplex technology to conduct gene polymorphism analysis of eight exons of the *Nurr1* gene in Parkinson\'s disease patients from the Han population living in the Hubei province, China.

RESULTS {#sec1-2}
=======

Quantitative analysis and clinical information of involved subjects {#sec2-1}
-------------------------------------------------------------------

In this study, 200 sporadic Parkinson\'s disease patients, including 110 males and 90 females (average age 62.03 ± 0.67 years) and 200 healthy controls consisting of 100 males and 100 females (average age 60.08 ± 0.82 years) were included. All subjects entered the final analysis. Clinical information for the Parkinson\'s disease patients and healthy controls is shown in [Table 1](#T1){ref-type="table"}.

###### 

Clinical characteristics of the participants
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Exons 2 and 3 of the *Nurr1* gene containing gene polymorphisms in Parkinson\'s disease patients {#sec2-2}
------------------------------------------------------------------------------------------------

We applied heteroduplex technology\[[@ref15][@ref16][@ref17][@ref18][@ref19]\] to conduct fragment analysis of eight exons of *Nurr1*; abnormal electrophoresis fragments were subcloned and DNA sequencing was performed. We identified one allele amplified from exon 3 of *Nurr1* that was polymorphic in five Parkinson\'s disease patients (5/200). Two individuals presented a polymorphic allele amplified from exon 2 (2/200), but no polymorphic allele existed in the healthy controls.

Gene mutation of exons 2 and 3 of *Nurr1* in Parkinson\'s disease patients {#sec2-3}
--------------------------------------------------------------------------

By DNA sequencing, we found that the anomalous electrophoretic fragment in exon 3 of the *Nurr1* gene contained a 709C/A missense mutation ([Figure 1](#F1){ref-type="fig"}). This mutation would change the 125^th^ serine into tyrosine, affecting *Nurr1* serine phosphorylation. However, further analysis needs to be carried out to determine the effect of the 388G/A polymorphism in exon 2 ([Figure 2](#F2){ref-type="fig"}) on *Nurr1* function, as exon 2 is part of the *Nurr1* promoter region.

![DNA sequencing diagram of 709C/A missense mutations in exon 3 of the *Nurr1* gene.](NRR-7-1791-g002){#F1}

![DNA sequencing diagram of 388G/A missense mutations in exon 2 of the *Nurr1* gene.\
(A) Mutant; (B) wild-type. Arrows represent mutation sites.](NRR-7-1791-g003){#F2}

*Nurr1* gene level decreased in Parkinson\'s disease patients {#sec2-4}
-------------------------------------------------------------

Compared with the control group, the *Nurr1* gene expression level of Parkinson\'s disease group was decreased (*P* \< 0.05). The *Nurr1* gene expression levels in Parkinson\'s disease patients carrying the polymorphisms at exons 2 and 3 were significantly decreased compared with the control group (*P* \< 0.01; [Table 2](#T2){ref-type="table"}).

###### 

*Nurr1* gene expression level (*Ct* value by real-time PCR) in blood
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DISCUSSION {#sec1-3}
==========

*Nurr1* is highly expressed in the developing and adult ventral midbrain and is required for the acquisition and maintenance of the dopaminergic phenotype in nigrostriatal neurons\[[@ref20]\]. It has been reported that, besides the central nervous system, *Nurr1* is expressed in many other tissues including peripheral blood lymphocytes\[[@ref21][@ref22][@ref23]\]. Using quantitative real-time PCR amplification\[[@ref24][@ref25][@ref26][@ref27]\], we analyzed the *Nurr1* gene level in the peripheral blood lymphocytes of 200 sporadic Parkinson\'s disease patients and 200 healthy controls and found that the *Nurr1* expression level in the *de novo* Parkinson\'s disease group was significantly decreased compared with that in the healthy control group, especially in several patients carrying two polymorphisms in exons 2 and 3 of *Nurr1*, indicating that these mutations exert a down-regulating effect on the expression of *Nurr1* in peripheral blood lymphocytes.

Studies on postmortem brains have found that an age-related decline in the levels of DA phenotypic markers is associated with down-regulation of Nurr1 expression in the human substantia nigra\[[@ref28][@ref29]\]. Chu and colleagues reported that the optical density of Nurr1 immunofluorescence was significantly decreased in nigral neurons containing α-synuclein-immunoreactive inclusions in Parkinson\'s disease patients\[[@ref30][@ref31]\]. Therefore, we investigated whether the *Nurr1* gene level in peripheral blood lymphocytes could exactly reflect the change in the disease stage in Parkinson\'s disease patients. In the present study, we obtained similar results, similar to Le\'s report that the *Nurr1* gene level in human peripheral blood lymphocytes revealed a significant decrease in individuals with Parkinson\'s disease and parkinsonian syndromes\[[@ref32]\].

In conclusion, our present data showed that a single nucleotide polymorphism 388G/A in exon 2 and a 709C/A missense mutation in exon 3 of the *Nurr1* gene exist in the Chinese population and might affect the pathogenesis in Parkinson\'s disease patients.

SUBJECTS AND METHODS {#sec1-4}
====================

Design {#sec2-5}
------

A gene polymorphic analysis.

Time and setting {#sec2-6}
----------------

The study was performed at the Zhongnan Hospital Affiliated to Wuhan University, China from January 2009 to October 2011.

Subjects {#sec2-7}
--------

Parkinson\'s disease patients were recruited from the Out-Patients Facility of Parkinson Clinic Center in Zhongnan Hospital, Wuhan University, China from 2009 to 2011.

### Inclusion criteria {#sec3-1}

(1)Patients were diagnosed according to the UK Parkinson\'s Disease Society Brain Bank Clinical Diagnostic Criteria for Parkinson\'s Disease\[[@ref33]\].(2)All came from the Hubei Province of China.(3)All patients were of Han ethnicity.(4)Patients and their families signed an informed consent form.

Healthy physical examination controls were randomly selected from the Health Examination Center in Zhongnan Hospital, Wuhan University, China. In total, 200 sporadic Parkinson\'s disease patients and 200 healthy controls were enrolled in this study, and matched for age, sex and ethnicity.

Methods {#sec2-8}
-------

### Nurr1 DNA analysis {#sec3-2}

Whole blood samples were collected from the upper limb veins of Parkinson\'s disease patients and healthy controls. Genomic DNA was extracted from 4 mL of whole blood using the QIA-amp DNA Mini Kit (QIAGEN, Dusseldorf, Germany) according to the manufacturer\'s protocols. Extracted genomic DNA samples were stored at −80°C until gene analysis was carried out. The primer pairs used to amplify *Nurr1* alleles were designed using the Primer3 (v. 0.4.0) system (PREMIER Biosoft International, Palo Alto, USA).

*Nurr1* PCR amplification primers and conditions are as follows:
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Briefly, eight exon-specific primer pairs were used to amplify exons 1--8 of *Nurr1* using a thermal cycler (model 9700, Applied Biosystems, Foster City, CA, USA). PCR products were electrophoresed through 4% acrylamide gels for 2 hours and abnormal alleles were sequenced using an ABI Prism 3100 Genetic Analyzer (Applied Biosystems). Sequence data were analyzed using Match Tools and Navigator software (Match Tools Allele Identification package, Applied Biosystems). The expression level of *Nurr1* gene was assessed as the average Ct value using real-time PCR in all Parkinson\'s disease patients and healthy controls.

### Statistical analysis {#sec3-3}

Data are expressed as mean ± SEM and were analyzed using SPSS 16.0 software (SPSS, Chicago, IL, USA). Comparisons between groups were performed using the chi-square test and Student\'s *t*-test.
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